Close Menu
  • Homepage
  • Local News
  • India
  • World
  • Politics
  • Sports
  • Finance
  • Entertainment
  • Business
  • Technology
  • Health
  • Lifestyle
Facebook X (Twitter) Instagram
  • Contact
  • Privacy Policy
  • Terms & Conditions
  • DMCA
Facebook X (Twitter) Instagram Pinterest
JHB NewsJHB News
  • Local
  • India
  • World
  • Politics
  • Sports
  • Finance
  • Entertainment
Let’s Fight Corruption
JHB NewsJHB News
Home»Finance»BMO Capital Maintains a Buy on Regeneron Pharmaceuticals (REGN), Sets a $640 PT
Finance

BMO Capital Maintains a Buy on Regeneron Pharmaceuticals (REGN), Sets a $640 PT

September 15, 2025No Comments2 Mins Read
Facebook Twitter Pinterest LinkedIn Tumblr Email
BMO Capital Maintains a Buy on Regeneron Pharmaceuticals (REGN), Sets a $640 PT
Share
Facebook Twitter LinkedIn Pinterest Email

Regeneron Prescription drugs, Inc. (NASDAQ:REGN) is without doubt one of the finest low cost shares to purchase for novices. In a report launched on September 8, Evan Seigerman from BMO Capital maintained a Purchase ranking on Regeneron Prescription drugs, Inc. (NASDAQ:REGN), setting a worth goal of $640.00.

Why Regeneron Pharmaceuticals, Inc. (REGN) Crashed Last Week
Why Regeneron Prescription drugs, Inc. (REGN) Crashed Final Week

The analyst cited varied components supporting the optimistic outlook, together with the promising outcomes from its latest Part 3 trials for the cat and birch allergy antibody cocktails.

The info confirmed appreciable symptom reductions, resembling pores and skin prick reactivity, ocular itch, and conjunctival redness. Sufferers with cat allergy symptoms pushed by the FelD1 allergen exhibited particularly robust outcomes.

Based on Seigerman, these outcomes recommend sturdy medical efficacy with the potential to deal with a substantial unmet want in allergy therapy.

Regeneron Prescription drugs, Inc. (NASDAQ:REGN) is a pharmaceutical firm that develops, discovers, and commercializes therapies for a number of illnesses, together with most cancers, eye problems, and allergic circumstances.

It has relied on two major merchandise to drive top-line development prior to now years: Dupixent and Eylea. Dupixent is an eczema therapy whose rights Regeneron Prescription drugs, Inc. (NASDAQ:REGN) shares with Sanofi. Eylea, which Regeneron Prescription drugs, Inc. (NASDAQ:REGN) comarkets with Bayer, treats moist age-related macular degeneration.

Whereas we acknowledge the potential of REGN as an funding, we imagine sure AI shares provide higher upside potential and carry much less draw back danger. If you happen to’re on the lookout for a particularly undervalued AI inventory that additionally stands to learn considerably from Trump-era tariffs and the onshoring development, see our free report on the finest short-term AI inventory.

READ NEXT: 30 Shares That Ought to Double in 3 Years and 11 Hidden AI Shares to Purchase Proper Now.

Disclosure: None. This text is initially revealed at Insider Monkey.

Source link

BMO Buy capital maintains Pharmaceuticals Regeneron REGN Sets
Share. Facebook Twitter Pinterest LinkedIn Tumblr Email

Related Posts

Lower Mortgage review 2026

March 13, 2026

Is Nasdaq Stock Outperforming the Dow?

March 13, 2026

Why take-home pay wins for workers this tax season

March 13, 2026

What is a multi-year guaranteed annuity (MYGA), and how does it work?

March 13, 2026
Add A Comment
Leave A Reply Cancel Reply

Editors Picks

Lower Mortgage review 2026

March 13, 2026

Hollywood on Alert Amid Threats Iran Could Strike the Oscars with Drone

March 13, 2026

Google Play Games Gets Game Trials and AI Tips

March 13, 2026

Is Nasdaq Stock Outperforming the Dow?

March 13, 2026
Popular Post

Adani founders to prepay loans worth $1.1 billion amid rout

These 3 Stocks Will Soar if Trump Wins in November

Cold storage provider Lineage announces expansion in Canada

Subscribe to Updates

Get the latest news from JHB News about Bangalore, Worlds, Entertainment and more.

JHB News
Facebook X (Twitter) Instagram Pinterest
  • Contact
  • Privacy Policy
  • Terms & Conditions
  • DMCA
© 2026 Jhb.news - All rights reserved.

Type above and press Enter to search. Press Esc to cancel.